Bioequivalence of macitentan and tadalafil given as fixed‐dose combination or single‐component tablets in healthy subjects
Authors:
Open Access
- 6 May 2020
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 86 (12) , 2424-2434
Abstract
Aims: To demonstrate the bioequivalence of macitentan/tadalafil fixed‐dose combination (FDC) tablets with single‐component tablets of macitentan and tadalafil in healthy subjects.Methods: Studies AC‐077‐101 and AC‐077‐103 were single‐centre, open‐label, single‐dose, 2‐period, randomized, crossover Phase 1 studies conducted in healthy subjects. Two FDCs were investigated: FDC‐1 and FDC‐2 in Study AC‐077‐101 and FDC‐2 in Study AC‐077‐103. Both FDCs contained 10 mg/40 mg of macitentan/tadalafil and differed in excipients and coating materials used. In both studies, pharmacokinetic sampling over 216 hours was conducted, and pharmacokinetic parameters were derived using noncompartmental methods.Results: Bioequivalence of macitentan, its active metabolite ACT‐132577, and tadalafil was established for FDC‐2 in both studies AC‐077‐101 and AC‐077‐103 in which tadalafil as a single component was sourced from the USA and EU, respectively, to fulfil regional regulatory requirements. The area under the plasma concentration–time curve and maximum plasma concentration with 90% confidence intervals of all components were entirely within the bioequivalence limits (0.8000–1.2500). No subject died and no serious adverse events were reported in either studies.Conclusion: The FDC‐2 tablet containing 10 mg/40 mg of macitentan/tadalafil was bioequivalent to the free combination of 10 mg macitentan and 40 mg tadalafil (both US and EU sourced). Macitentan and tadalafil were well tolerated when administered as FDC or as a free combination.Keywords
Funding Information
- Janssen Research and Development
This publication has 9 references indexed in Scilit:
- Bioequivalence of macitentan and tadalafil given as fixed‐dose combination or single‐component tablets in healthy subjectsBritish Journal of Clinical Pharmacology, 2020
- Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist MacitentanClinical Pharmacokinetics, 2015
- Updated Treatment Algorithm of Pulmonary Arterial HypertensionJACC, 2013
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionNew England Journal of Medicine, 2013
- Macitentan: entry-into-humans study with a new endothelin receptor antagonistEuropean Journal of Clinical Pharmacology, 2011
- The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertensionVascular Health and Risk Management, 2010
- Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2009
- Tadalafil pharmacokinetics in healthy subjectsBritish Journal of Clinical Pharmacology, 2005
- Survival in Patients with Primary Pulmonary HypertensionAnnals of Internal Medicine, 1991